UBS Group
THRD

UBS Group’s Third Harmonic Bio THRD Stock Holding History

UBS Group’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,256
Closed -$284K – 10924
2025
Q2 		$284K Buy
52,256
+4,084
+8% +$20.4K ﹤0.01% 6479
2025
Q1 		$167K Buy
48,172
+34,856
+262% +$169K ﹤0.01% 6661
2024
Q4 		$137K Buy
13,316
+2,431
+22% +$30.3K ﹤0.01% 6684
2024
Q3 		$147K Buy
10,885
+3,104
+40% +$38.5K ﹤0.01% 6083
2024
Q2 		$101K Sell
7,781
-11,915
-60% -$147K ﹤0.01% 6153
2024
Q1 		$186K Sell
19,696
-2,196
-10% -$21.3K ﹤0.01% 5905
2023
Q4 		$240K Buy
21,892
+11,246
+106% +$89.1K ﹤0.01% 5655
2023
Q3 		$68K Sell
10,646
-613
-5% -$3.75K ﹤0.01% 6091
2023
Q2 		$54.2K Buy
11,259
+7,212
+178% +$34.3K ﹤0.01% 6427
2023
Q1 		$16.7K Sell
4,047
-3,014
-43% -$12.8K ﹤0.01% 7222
2022
Q4 		$30.4K Buy
7,061
+5,809
+464% +$97.2K ﹤0.01% 7230
2022
Q3 		$24K Buy
+1,252
New +$22.6K ﹤0.01% 7157

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS Group's THRD Position: Q3 2025 in Review

UBS Group sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 52,256 shares — an estimated $284K sold.

UBS Group first reported a position in THRD in Q3 2022 and held it in 12 quarters. The position peaked at $284K in Q2 2025. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • UBS Group reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 52,256 Third Harmonic Bio shares in Q3 2025, an estimated $284K.
  • UBS Group first reported a position in Third Harmonic Bio in Q3 2022 and held it in 12 quarters.
  • UBS Group's Third Harmonic Bio position peaked at $284K in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.